Related references
Note: Only part of the references are listed.Surge in Expression of Carboxylesterase 1 During the Post-neonatal Stage Enables a Rapid Gain of the Capacity to Activate the Anti-influenza Prodrug Oseltamivir
Deshi Shi et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak
P. S. Pannaraj et al.
JOURNAL OF PERINATOLOGY (2011)
Pharmacologic Considerations for Oseltamivir Disposition Focus on the Neonate and Young Infant
Susan M. Abdel-Rahman et al.
PEDIATRIC DRUGS (2011)
Oseltamivir Dosing for Influenza Infection in Premature Neonates
Edward P. Acosta et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Influenza-associated deaths among children in the United States, 2003-2004
N Bhat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Experience with oseltamivir for infants younger than 1 year old in Japan
S Okamoto et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2005)
Resistant influenza A viruses in children treated with oseltarnivir: descriptive study
M Kiso et al.
LANCET (2004)
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years
C Oo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine
H Wiltshire et al.
JOURNAL OF CHROMATOGRAPHY B (2000)
Share Paper
